Akili Interactive (EndeavorRx, EndeavorOTC)

Akili Interactive (Subsidiary of Virtual Therapeutics)

First FDA-cleared video game digital therapeutic for ADHD in children and adults.

About Akili Interactive (EndeavorRx, EndeavorOTC)

Akili Interactive pioneered video game-based digital therapeutics with EndeavorRx, which became the first FDA-cleared video game treatment in June 2020. Originally approved for children ages 8-12 with inattentive or combined-type ADHD, FDA expanded the label in 2024 to include adolescents 13-17, more than doubling the eligible patient population. In June 2024, Akili received FDA clearance for EndeavorOTC, the first FDA-authorized over-the-counter digital treatment for adults with ADHD. The treatments use the same proprietary SSME (Selective Stimulus Management Engine) technology to target attention through adaptive, engaging gameplay. While Akili found the prescription model challenging for building a sustainable business, the OTC expansion addresses the growing adult ADHD market. Akili merged with Virtual Therapeutics in 2024, becoming a private company subsidiary.

Best For

  • Pediatricians and child psychiatrists treating ADHD in children ages 8-17
  • Adult psychiatrists seeking non-pharmacological ADHD adjunct treatments
  • Parents looking for FDA-cleared, engaging ADHD interventions
  • Patients preferring gamified therapeutic approaches

Not Ideal For

  • Children under 8 years old
  • Patients seeking standalone ADHD treatment (designed as adjunct)
  • Organizations seeking enterprise MBC platforms
  • Those with photosensitive epilepsy (contraindicated)

Pricing

$99/30 days (EndeavorRx) or $69.99/3 months (EndeavorOTC)

Compliance & Security

HIPAAYes
BAA AvailableUnknown
SOC 2Unknown
HITRUSTUnknown

Always verify compliance directly with the vendor.

Target Audience

Roles

Psychiatrist

Settings

Integrated Care

Get Started

Try Akili Interactive (EndeavorRx, EndeavorOTC) for your practice.

Visit Akili Interactive (EndeavorRx, EndeavorOTC)